Claims for Patent: 10,933,060

Summary for Patent: 10,933,060

Title:	Pharmaceutical compositions and methods of using the same
Abstract:	Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
Inventor(s):	Moshal; Jeffrey M. (Allentown, PA), Libman; Michael (Allentown, PA)
Assignee:	GENUS LIFESCIENCES INC. (Allentown, PA)
Application Number:	16/904,104
Patent Claims:	1. A method for induction of local anesthesia prior to performing a medical procedure on, through, or adjacent to a mucous membrane of a nasal cavity of a patient comprising: soaking four absorbent articles with an aqueous solution comprising, by weight, about 36 mg/mL to about 44 mg/mL of cocaine hydrochloride, 1.2 mg/mL to 1.4 mg/mL citric acid, 0.7 mg/mL to 1.3 mg/mL sodium benzoate, and water; and contacting the absorbent articles with the mucous membrane in a nasal cavity of the patient for up to about 20 minutes to reduce sensation in a body region of the patient; provided that the method results in an absorptivity factor for cocaine in the patient ranging from about 0.25 h.sup.-1 to about 1.0 h.sup.-1. 2. The method of claim 1, wherein the absorbent articles comprise pledgets. 3. The method of claim 2, wherein the pledgets comprise cottonoid pledgets. 4. The method of claim 1, wherein each pledget is removed from the nasal cavity and retains between about 70% and about 80% of the cocaine hydrochloride. 5. The method of claim 1, wherein the medical procedure performed is selected from the group consisting of a nasal endoscopy, a nasal laryngoscopy, a nasopharyngeal laryngoscopy, and a nasal debridement. 6. The method of claim 5, wherein the procedure is a nasal endoscopy. 7. The method of claim 5, wherein the procedure is a nasal laryngoscopy. 8. The method of claim 5, wherein the procedure is a nasopharyngeal laryngoscopy. 9. The method of claim 5 wherein the procedure is a nasal debridement. 10. The method of claim 1, wherein the method results in a T.sub.max ranging from about 0.02 hours to about 1.00 hours. 11. The method of claim 1 wherein the method results in an AUC.sub.inf in a range from about 25.0 ng*h/mL to about 370 ng*h/mL of cocaine in the patient. 12. The method of claim 1 wherein the method results in a reduction in pain equivalent to achieving a visual numeric rating score of 0 upon von Frey filament testing.